Innovaderm is well-positioned to optimize the management of your clinical programs. Our full-service CRO allocates resources, teams and technologies to support your projects and ultimately enhance their success. In short, we leverage our 20+ years of clinical research experience in dermatology to assist you in your journey to drug discovery that may culminate in novel therapies for people with skin disease.
No matter how complex your project is, Innovaderm will assist your team in achieving streamlined clinical development for your phase 2B-3 studies.
Through the evaluation of protocol and recruitment objectives, our dermatology experts can successfully resolve issues surrounding regulatory requirements, patient and site recruitment challenges, protocol designs and procedures, and patient-reported outcomes.
In addition, our customized approach to problem-solving can help you manage costs and mitigate risks that are inherent to your clinical projects.
With moving parts such as study design, regulatory requirements and project optimization, early-phase clinical research is constantly evolving. Innovaderm’s team of dermatology experts can support your early development programs to help you reach key data milestones both for topical and systemic compounds.
We manage phase I, Proof of Concept (POC) and First-in-Man (FIM) single center and multicenter studies where we leverage our Clinical Research Unit for operational synergies.
Innovaderm functions strictly in accordance with Standard Operating Procedures (SOPs) to meet current Good Clinical Practice (GCP) from the International Conference of Harmonization (ICH). It is also fully compliant with major international regulations such as the FDA (USA), Health Canada and EMA (Europe).
"With the powerful combination of rigor & innovation that their team brings, we were able to execute our study smoothly and deliver results showing profound potential for patients."
"There are many CRO partners out there, but Innovaderm stands out among them as a dedicated, committed partner to their sponsors."
